Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):719-720. Epub 2017 Mar 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens / genetics
  • Carrier Proteins / genetics
  • Chemokine CXCL9 / genetics
  • Cytoskeletal Proteins / genetics
  • Female
  • GTP-Binding Proteins / genetics
  • Humans
  • Immunoglobulin A / immunology
  • Immunoglobulin G / immunology
  • Immunoglobulin M / immunology
  • Immunosuppressive Agents / therapeutic use*
  • Interferon Type I / immunology
  • Interferon-gamma / immunology
  • Middle Aged
  • Myxovirus Resistance Proteins / genetics
  • RNA-Binding Proteins
  • Real-Time Polymerase Chain Reaction
  • Rheumatoid Factor / immunology
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / immunology
  • Treatment Outcome

Substances

  • Adaptor Proteins, Signal Transducing
  • Antibodies, Monoclonal, Humanized
  • Antigens
  • CXCL9 protein, human
  • Carrier Proteins
  • Chemokine CXCL9
  • Cytoskeletal Proteins
  • GBP1 protein, human
  • IFI44 protein, human
  • IFIT1 protein, human
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M
  • Immunosuppressive Agents
  • Interferon Type I
  • MX1 protein, human
  • Myxovirus Resistance Proteins
  • RNA-Binding Proteins
  • belimumab
  • Interferon-gamma
  • Rheumatoid Factor
  • GTP-Binding Proteins